ClinicalTrials.gg
Not yet recruitingNCT07536919MULTI-HEARTSUpdated Nov 12, 2026

Implementation Support for HEARTS-Based Hypertension and Diabetes Care in Guatemala

An interventional study of HEARTS implementation support and Routine HEARTS implementation in Hypertension (HTN) and Type 2 Diabetes, sponsored by University of Michigan. Not yet recruiting at 1 site in Guatemala. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Michigan · Not applicable, Interventional, and Health services research

How we know

Updated Nov 12, 2026First site in GuatemalaStart date moved+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,440
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Hypertension by University of Michigan — 1 open to participants now, 1 under way, none of them phase 3. Hypertension · University of Michigan.

Planned enrollment
Largest of 26
1,440 · median 94
Started
2027
the only one that year
No phase
22 of 28
1 open now
Registered
28th of 28
by date

Among the 28 studies in Hypertension by University of Michigan, this one has the largest planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2027, is one of 22 with no phase, and was the 28th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 28 studies in Hypertension by University of Michigan is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Hypertension by University of Michigan, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether extra support for a program called HEARTS can improve care for people who have both high blood pressure and diabetes. HEARTS was created by the World Health Organization to help primary care health centers deliver better treatment. It is the official model for high blood pressure and diabetes care in Guatemala's Ministry of Health. In this study, 36 Ministry of Health health centers in Guatemala will be randomly assigned to 1 of 2 groups. Health centers in both groups will use HEARTS through the Ministry of Health's routine training, treatment guides, and digital tools. Health centers in 1 group will also receive 36 months of extra support from the Institute of Nutrition of Central America and Panama (INCAP). This support includes refresher training for health workers every 6 months, monthly supportive supervision visits, and coaching of a health center quality committee to use data to improve care. About 1,440 adults who have both high blood pressure and diabetes will take part. Participants will be assessed at the start of the study, at 6 months, and at 12 months. The main measure is systolic blood pressure at 12 months. The most important other measure is hemoglobin A1c (a blood test that shows average blood sugar levels over the past 2 to 3 months) at 12 months.

Read the detailed description

MULTI-HEARTS is a cluster-randomized, hybrid type 2 effectiveness-implementation trial of implementation support for HEARTS, the official model for hypertension and diabetes primary care in Guatemala's Ministry of Health. Health centers in both arms will implement HEARTS through the Ministry of Health's routine strategies. In the implementation support arm, health centers also will receive additional implementation support strategies directed at health workers, managers, and support staff.

The primary objective is to evaluate whether HEARTS implementation support leads to better hypertension and diabetes control than routine HEARTS implementation among adults with hypertension and diabetes. We hypothesize that implementation support will lead to lower mean systolic blood pressure at 12 months (primary outcome) compared to routine HEARTS implementation. The key secondary outcome is mean hemoglobin A1c (HbA1c) at 12 months. Other secondary outcomes are mean diastolic blood pressure and the proportions of participants with blood pressure control, HbA1c control, and combined blood pressure and HbA1c control at 12 months. The primary implementation outcome is Reach, which is defined in the study to be the monthly number of patients treated with both antihypertensive and glucose-lowering medications at participating health centers. In an economic evaluation, we will also estimate costs, cost-effectiveness, and budget impact.

We will randomize 36 Ministry of Health health centers in a 1:1 ratio, with stratification by health area. We will enroll 1,440 adults aged 18 years or older with systolic blood pressure ≥130 mmHg and HbA1c ≥6.5%. There will be approximately 40 participants per health center and a total of 720 per arm. Allowing for 15% attrition, the trial will have at least 80% power to detect a between-arm difference of 5.0 mmHg in mean systolic blood pressure at 12 months. The health centers serve urban and rural communities, and many participants will live in poverty and have limited literacy. Some trial participants are expected to be Indigenous Maya and will primarily speak a Mayan language rather than Spanish.

After a 1-year trial planning period, health centers will be randomized before the start of the 36-month implementation period. Each participant will be followed for 12 months. Ministry of Health administrative data will also be collected for a 6-month post-trial period. In addition to the trial data, the study includes additional data collection for implementation and economic evaluations.

03

Conditions studied

  • Hypertension (HTN)
  • Type 2 Diabetes

Keywords

  • implementaton support
  • hearts
  • hybrid effectiveness-implementation trial
  • cluster-randomized trial
  • primary health care
  • multimorbidity
  • Guatemala
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Blood pressure criteria, defined as mean systolic blood pressure of ≥130 mmHg at the screening visit and again at the enrollment visit, held 1 to 14 days apart.
  • Glycemic criteria, defined as one of the following: (a) for individuals with a prior diagnosis of diabetes or currently taking a glucose-lowering drug, of ≥6.5% at the screening visit; (b) for individuals without a prior diagnosis of diabetes and not taking a glucose-lowering drug, HbA1c of ≥6.5% at both the screening and enrollment visits.
  • Living in a community served by one of the health centers included in the study and willing to receive health care at the corresponding health center.
  • Provides in Spanish or the main Mayan language in the municipality where they live.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or planning pregnancy during the 12-month follow-up period, based on self-report.
  • Type 1 diabetes, based on self-reported medical history or the judgment of the study physician.
  • Illness that, in the judgment of the study physician, limits to less than 12 months or would prevent completion of study follow-up, including but not limited to end-stage kidney disease requiring or awaiting dialysis, advanced heart failure, liver failure, or cancer under active treatment.
  • Currently participating in another research study involving an intervention.
  • Planning to leave the community served by the health center during the 12-month follow-up period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,440 participants (estimated)

Study arms

  • Experimental
    Implementation support arm

    Routine HEARTS implementation with additional implementation support from INCAP for 36 months.

    Other: HEARTS implementation support · Other: Routine HEARTS implementation

  • Active comparator
    Routine implementation arm

    Routine HEARTS implementation alone.

    Other: Routine HEARTS implementation

Interventions

  • OtherHEARTS implementation support

    Group refresher training every 6 months, monthly supportive supervision visits, and data-driven coaching of a health center quality committee, delivered by INCAP implementation support physicians to health workers, managers, and support staff.

  • OtherRoutine HEARTS implementation

    An initial training-of-trainers workshop, Clinical Pathways for hypertension and type 2 diabetes, and digital tools, delivered by the Ministry of Health under its National Strategy for Cardio-Reno-Metabolic Risk Management based on HEARTS.

06

What researchers measure

Primary outcomes

  1. Systolic blood pressure

    Between-arm mean difference in systolic blood pressure, using the mean of 3 automated readings.

    Time frame: 12 months after the enrollment visit

Secondary outcomes

  1. Hemoglobin A1c

    Key secondary outcome. Between-arm mean difference in hemoglobin A1c, measured with a point-of-care device.

    Time frame: 12 months after the enrollment visit

  2. Diastolic blood pressure

    Between-arm mean difference in diastolic blood pressure, using the mean of 3 automated readings.

    Time frame: 12 months after the enrollment visit

  3. Proportion of participants with blood pressure control

    Between-arm difference in the proportion of participants with blood pressure control of \<130/\<80 mmHg, as defined in national guidelines.

    Time frame: 12 months after the enrollment visit

  4. Proportion of participants with hemoglobin A1c control

    Between-arm difference in the proportion of participants with hemoglobin A1c control of \<7.0%, as defined in national guidelines.

    Time frame: 12 months after the enrollment visit

  5. Proportion of participants with combined blood pressure control and hemoglobin A1c control

    Between-arm difference in the proportion of participants with combined blood pressure control (\<130/\<80 mmHg) and hemoglobin A1c control (\<7.0%), as defined in national guidelines.

    Time frame: 12 months after the enrollment visit

07

Study locations

1 site
  • Ministry of Health health centers
    Guatemala City, Guatemala
08

References and documents

Individual participant data

Plan to share: Yes — We will deposit de-identified participant-level data collected at study visits in a data repository selected in accordance with NHLBI policy.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: No later than the time of an associated publication or the end of the performance period, whichever comes first.

Access criteria: The repository will control access to the data in accordance with NHLBI policy.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2027; primary completion for Sep 2030, 35 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 35 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start May 2027 → Oct 2027, primary completion May 2030 → Sep 2030 and completion May 2030 → Sep 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2026
First posted
Apr 17, 2026
StartEst.
Oct 2027was May 2027
Primary completionEst.
Sep 2030was May 2030
CompletionEst.
Sep 2030was May 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Guatemala
Show site
  • Ministry of Health health centers · Guatemala City, Guatemala
Nov 12, 2026
Start date
May 1, 2027→Oct 2027
Nov 12, 2026
Primary completion
May 1, 2030→Sep 2030
Nov 12, 2026
Study completion
May 1, 2030→Sep 2030
Nov 12, 2026
Eligibility
Criteria largely rewritten (20 changes)
What changed in the criteria
Inclusion criteria
  • EditedAge ≥18 years or older.
  • RemovedSystolic blood pressure ≥130 mmHg on ≥2 occasions, defined as the mean of 6 measurements at 2 study visits scheduled at least 1 day apart but within 7 days
  • RemovedHemoglobin A1c ≥6.5%
  • RemovedAble and willing to provide informed consent
  • AddedBlood pressure criteria, defined as mean systolic blood pressure of ≥130 mmHg at the screening visit and again at the enrollment visit, held 1 to 14 days apart.
  • AddedGlycemic criteria, defined as one of the following: (a) for individuals with a prior diagnosis of diabetes or currently taking a glucose-lowering drug, HbA1c of ≥6.5% at the screening visit; (b) for individuals without a prior diagnosis of diabetes and not taking a glucose-lowering drug, HbA1c of ≥6.5% at both the screening and enrollment visits.
  • AddedLiving in a community served by one of the health centers included in the study and willing to receive health care at the corresponding health center.
  • AddedProvides informed consent in Spanish or the main Mayan language in the municipality where they live.
Exclusion criteria
  • RemovedDoes not live in Health Center's catchment area or is unwilling to receive care at the Health Center
  • RemovedCurrently pregnant or planning pregnancy in the next 2 years
  • RemovedHas been diagnosed with type 1 diabetes, or there is high suspicion of this diagnosis by study physicians
  • RemovedHas severe chronic or terminal illness such that primary care management of hypertension and/or diabetes would be clinically inappropriate, including end-stage kidney disease
  • RemovedConfined to bed
  • RemovedPlanning to leave the study area in the next 2 years
  • RemovedUnwilling to comply with protocol requirements
  • AddedPregnant or planning pregnancy during the 12-month follow-up period, based on self-report.
  • AddedType 1 diabetes, based on self-reported medical history or the judgment of the study physician.
  • AddedIllness that, in the judgment of the study physician, limits life expectancy to less than 12 months or would prevent completion of study follow-up, including but not limited to end-stage kidney disease requiring or awaiting dialysis, advanced heart failure, liver failure, or cancer under active treatment.
  • AddedCurrently participating in another research study involving an intervention.
  • AddedPlanning to leave the community served by the health center during the 12-month follow-up period.
Nov 12, 2026
Interventions
Added HEARTS implementation support·Routine HEARTS implementation; removed HEARTS implementation strategies·Supply chain strengthening. Arms added: Implementation support arm·Routine implementation arm; arms removed: HEARTS Integrated Hypertension-Diabetes Care·Enhanced Usual Care
Nov 12, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedChange in systolicSystolic blood pressureTime frame: Enrollment to 12 months → 12 months after the enrollment visit
  • RemovedChange in hemoglobin A1cTime frame: Enrollment to 12 months
Nov 12, 2026
Secondary outcomes
4 edited, 1 added
What changed in the outcomes
  • EditedChange in diastolicDiastolic blood pressureTime frame: Enrollment to 12 months → 12 months after the enrollment visit
  • EditedProportion of participants with blood pressure controlTime frame: Enrollment to 12 months → 12 months after the enrollment visit
  • EditedProportion with hemoglobinHemoglobin A1c controlTime frame: 12 months → 12 months after the enrollment visit
  • EditedProportion of participants with combined blood pressure and hemoglobin A1c controlTime frame: 12 months → 12 months after the enrollment visit
  • AddedProportion of participants with combined blood pressure control and hemoglobin A1c controlTime frame: 12 months after the enrollment visit
Nov 12, 2026
Contact
Study contact changed: added p•••@mgb.org · •••5500. See the current contact
Nov 12, 2026
Title
Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation→Implementation Support for HEARTS-Based Hypertension and Diabetes Care in Guatemala
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    1 site added — first site in Guatemala
    Show site
    • Ministry of Health health centers · Guatemala City, Guatemala
    Start date May 1, 2027→Oct 2027
    Primary completion May 1, 2030→Sep 2030
    Study completion May 1, 2030→Sep 2030
    Eligibility Criteria largely rewritten (20 changes)
    What changed in the criteria
    Inclusion criteria
    • EditedAge ≥18 years or older.
    • RemovedSystolic blood pressure ≥130 mmHg on ≥2 occasions, defined as the mean of 6 measurements at 2 study visits scheduled at least 1 day apart but within 7 days
    • RemovedHemoglobin A1c ≥6.5%
    • RemovedAble and willing to provide informed consent
    • AddedBlood pressure criteria, defined as mean systolic blood pressure of ≥130 mmHg at the screening visit and again at the enrollment visit, held 1 to 14 days apart.
    • AddedGlycemic criteria, defined as one of the following: (a) for individuals with a prior diagnosis of diabetes or currently taking a glucose-lowering drug, HbA1c of ≥6.5% at the screening visit; (b) for individuals without a prior diagnosis of diabetes and not taking a glucose-lowering drug, HbA1c of ≥6.5% at both the screening and enrollment visits.
    • AddedLiving in a community served by one of the health centers included in the study and willing to receive health care at the corresponding health center.
    • AddedProvides informed consent in Spanish or the main Mayan language in the municipality where they live.
    Exclusion criteria
    • RemovedDoes not live in Health Center's catchment area or is unwilling to receive care at the Health Center
    • RemovedCurrently pregnant or planning pregnancy in the next 2 years
    • RemovedHas been diagnosed with type 1 diabetes, or there is high suspicion of this diagnosis by study physicians
    • RemovedHas severe chronic or terminal illness such that primary care management of hypertension and/or diabetes would be clinically inappropriate, including end-stage kidney disease
    • RemovedConfined to bed
    • RemovedPlanning to leave the study area in the next 2 years
    • RemovedUnwilling to comply with protocol requirements
    • AddedPregnant or planning pregnancy during the 12-month follow-up period, based on self-report.
    • AddedType 1 diabetes, based on self-reported medical history or the judgment of the study physician.
    • AddedIllness that, in the judgment of the study physician, limits life expectancy to less than 12 months or would prevent completion of study follow-up, including but not limited to end-stage kidney disease requiring or awaiting dialysis, advanced heart failure, liver failure, or cancer under active treatment.
    • AddedCurrently participating in another research study involving an intervention.
    • AddedPlanning to leave the community served by the health center during the 12-month follow-up period.
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedChange in systolicSystolic blood pressureTime frame: Enrollment to 12 months → 12 months after the enrollment visit
    • RemovedChange in hemoglobin A1cTime frame: Enrollment to 12 months
    Secondary outcomes 4 edited, 1 added
    What changed in the outcomes
    • EditedChange in diastolicDiastolic blood pressureTime frame: Enrollment to 12 months → 12 months after the enrollment visit
    • EditedProportion of participants with blood pressure controlTime frame: Enrollment to 12 months → 12 months after the enrollment visit
    • EditedProportion with hemoglobinHemoglobin A1c controlTime frame: 12 months → 12 months after the enrollment visit
    • EditedProportion of participants with combined blood pressure and hemoglobin A1c controlTime frame: 12 months → 12 months after the enrollment visit
    • AddedProportion of participants with combined blood pressure control and hemoglobin A1c controlTime frame: 12 months after the enrollment visit
    Interventions Added HEARTS implementation support·Routine HEARTS implementation; removed HEARTS implementation strategies·Supply chain strengthening. Arms added: Implementation support arm·Routine implementation arm; arms removed: HEARTS Integrated Hypertension-Diabetes Care·Enhanced Usual Care
    Contact Study contact changed: added p•••@mgb.org · •••5500. See the current contact
    Title Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation→Implementation Support for HEARTS-Based Hypertension and Diabetes Care in Guatemala
    + 6 other changes: verification date, responsible party, description, conditions, design details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07536919
Collaborators
Institute of Nutrition of Central America and Panama, Brigham and Women's Hospital, Wuqu' Kawoq, Maya Health Alliance, Washington University School of Medicine, University of Washington, National Heart, Lung, and Blood Institute (NHLBI), Ministry of Health, Guatemala
Responsible party
David Flood (Assistant Professor of Medicine, University of Michigan) — Principal investigator
First posted
Apr 17, 2026
Start date
Oct 2027 (estimated)
Primary completion
Sep 2030 (estimated)
Completion
Sep 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

David Flood, MD
Contact
dcflood@umich.edu
734-647-2892
Peter Rohloff, MD, PhD
Contact
prohloff@mgb.org
617-732-5500
David Flood, MD, MSc
principal investigator · University of Michigan
Peter Rohloff, MD, PhD
principal investigator · Brigham and Women's Hospital
Manuel Ramírez-Zea, MD, PhD
principal investigator · Institute of Nutrition of Central America and Panama

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion